Injective (INJ) is currently priced at $2.92, exhibiting a 24-hour decline of approximately 2.91%. The daily trading range has been narrow, with a high of $3.08 and a low of $2.90, indicating limited volatility in the short term.

Volume over the past 24 hours is reported at 37,733,152, which corresponds to a relatively high volume-to-market cap ratio of 12.94%. This suggests active trading interest despite the recent price drop, indicating that market participants are still engaging with the asset.

Moving averages reveal a mixed short-term outlook; the 8-period SMA is at $2.92 with a slight increase of 0.14%, while the 13-period SMA shows a decline of 0.27%. The longer-term SMAs are bearish, with the 55-period SMA at $3.00 down by 2.64%, signaling a potential resistance level.

The 1-hour Relative Strength Index (RSI) is at a critical level of 28, indicating that INJ may be oversold in the short term. In contrast, the 7-day RSI is neutral at 50, suggesting a lack of strong momentum in either direction, while the 30-day price change is negative at -6.85%, indicating a longer-term bearish trend.

Considering the all-time high of $52.62 reached earlier this year, the current price represents a significant retracement, which may attract bottom-fishing investors. However, the bearish signals from the moving averages and the low hourly RSI indicate that immediate upside potential is limited.

Given the current technical indicators and the recent price action, a cautious approach is warranted. The recommendation is to Hold INJ at this time, as further consolidation or a clearer trend direction is needed before making a decisive Buy or Sell action.